Table 2.
Phenotype of resistance | Number of isolates | Percentage of isolates |
---|---|---|
CRO | 1 | 2.17 |
STR | 1 | 2.17 |
ATM | 1 | 2.17 |
NALa | 5 | 10.8 |
KAN + NAL | 1 | 2.17 |
TET + STR | 1 | 2.17 |
NAL + TETa | 2 | 4.3 |
NAL + CRO | 1 | 2.17 |
AMC + CFZ + AMP | 1 | 2.17 |
SXT + CFZ + AMP | 1 | 2.17 |
SXT + CIP + NAL + TETa | 1 | 2.17 |
STX + NAL + TET + STRa | 1 | 2.17 |
SXT + TET + STR + AMP + CROa | 1 | 2.17 |
STX + TET + STR + AMP + CROa | 1 | 2.17 |
NA + TET + STR + AMP + CROa | 1 | 2.17 |
STX + CFZ + NAL + TET + AMPa | 1 | 2.17 |
SXT + SAM + CIP + NAL + TET + AMPa | 1 | 2.17 |
STX + SAM + CIP + NAL + TET + STR + AMPa | 1 | 2.17 |
STX + SAM + NAL + TET + AMP + CRO + ATMa | 1 | 2.17 |
CTX + CFZ + SAM + CPD + CRO + CIP + NAL + AMP + CROb | 1 | 2.17 |
CAZ + CTX + AMC + CFZ + SAM + CIP + CRO + AMP + ATMb | 1 | 2.17 |
a E. coli developed on the plate with ciprofloxacin; bE. coli developed on the plate with cefotaxime. TET, tetracycline; AMP, ampicillin; STR, streptomycin; STX, sulfamethoxazole-trimethoprim; CRO, ceftriaxone; CFZ, cefazolin; CPD, cefpodoxime; CAZ, ceftazidime; CTX, cefotaxime; ATM, aztreonam; NAL, nalidixic acid; CIP, ciprofloxacin; SAM, ampicillin-sulbactam; AMC, amoxicillin-clavulanic acid; GEN, gentamicin; KAN, kanamycin.